The purpose of this study is to determine if gevokizumab therapy may be an alternate therapy in patients with steroid resistant Autoimmune Inner Ear Disease.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
10
Long Island Jewish Medical Center, Hearing & Speech Center
New Hyde Park, New York, United States
Improved hearing threshold, as defined by an improvement in either the PTA (Pure Tone Average) of >=5 dB (Decibel), or 12% in the WRS (Word Recognition Score)
Time frame: Day 28 to Day 84
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.